Rising, yes, Q4 is very late. The "FDA End-of-Phase 2 meeting" is not clear to me. Could it mean that this is the last meeting to approve this application? Earlier in the presentation, they say, "Development pathway endorsed by FDA and EMA." There will be some new scientific info in the MDS and AAS meetings, but this info is ready much earlier than in Q4.
They also inform that in the 202 study, they have new things to inform: "glial pathology" with MRI, Alpha-synuclein in biomarkers, and autonomic function.
I do not believe that the needed FDA meeting has been booked. But, sure, it can be as late as Q4. However, ATH should know everything the FDA will need in Q3. BUT, of course, they know these things much better than I do here on my sofa. Just my opinion, and tired of waiting.
ATH Price at posting:
0.8¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)